Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failu...

Full description

Bibliographic Details
Main Authors:	Anastasia Stella Perpinia, Nikolaos Kadoglou, Maria Vardaka, Georgios Gkortzolidis, Apostolos Karavidas, Theodoros Marinakis, Chrysostomi Papachrysostomou, Panagiotis Makaronis, Charikleia Vlachou, Marina Mantzourani, Dimitrios Farmakis, Konstantinos Konstantopoulos
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Pharmaceuticals
Subjects:	leukemia lymphoma cardiotoxicity heart failure anthracyclines anticancer targeted therapies
Online Access:	https://www.mdpi.com/1424-8247/15/8/1007

Similar Items

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01)

A journey in anthracycline-induced cardiotoxicity with emphasizing on doxorubicin: a review article
by: Atlasi Safaei, et al.
Published: (2021-11-01)

Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)

Genetics of Anthracycline-Associated Cardiotoxicity
by: Talal Khalid Al-Otaibi, et al.
Published: (2022-04-01)

Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention
by: Yun Qiu, et al.
Published: (2023-12-01)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review
by: Roberto Rosenfeld, et al.
Published: (2022-06-01)

Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play
by: Maryam Moossavi, et al.
Published: (2023-03-01)

Incidence and risk factors of anthracycline-induced cardiotoxicity in long-term survivors of pediatric cancer: A population based cohort study
by: Prathana Nathan, et al.
Published: (2022-12-01)

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)

Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Anthracycline-Induced Cardiotoxicity
by: Jennifer E. Liu, MD
Published: (2020-03-01)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
by: Hui-Min Hu, et al.
Published: (2018-01-01)

Natural Products Counteracting Cardiotoxicity during Cancer Chemotherapy: The Special Case of Doxorubicin, a Comprehensive Review
by: Izabela Koss-Mikołajczyk, et al.
Published: (2021-09-01)

Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
by: Tian-Hu Wang, et al.
Published: (2023-11-01)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
by: Jacqueline T. Vuong, et al.
Published: (2022-04-01)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
by: Francesco Venturelli, et al.
Published: (2018-09-01)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
by: Becky Meiners, et al.
Published: (2018-08-01)

Value of Left Ventricular Global Longitudinal Strain Assessed by Two-Dimensional Strain Imaging in Early Detection of Anthracycline Mediated Cardiotoxicity
by: Yasser Abdel-Hady, et al.
Published: (2022-04-01)

Assessing cardiotoxicity in randomised trials of anthracycline chemotherapy
by: Kerr, A
Published: (2016)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
by: Aleksandra M. Sobiborowicz-Sadowska, et al.
Published: (2023-01-01)

Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review
by: Laura J. Philip, et al.
Published: (2022-12-01)

Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma
by: Emad Moussa, et al.
Published: (2017-03-01)

Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy
by: Kasey J. Leger, et al.
Published: (2017-04-01)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
by: Alexandros Briasoulis, et al.
Published: (2022-02-01)

Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials
by: Yingxu Ma, et al.
Published: (2019-04-01)

Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients
by: Xi Zhou, et al.
Published: (2023-10-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Longitudinal strain analysis for assessment of early cardiotoxicity during anthracycline treatment in childhood sarcoma: A single center experience
by: Maria Sjöborg Alpman, et al.
Published: (2023-09-01)

Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability
by: Emma L. Wilkinson, et al.
Published: (2016-10-01)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
by: Leila Mabudian, et al.
Published: (2022-09-01)

Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
by: Sibren Haesen, et al.
Published: (2024-01-01)

Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
by: Diogo Pereira Santos Sampaio, et al.
Published: (2022-10-01)

Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient specific care
by: Shayan Moazeni, et al.
Published: (2017-05-01)